Picture ConsulTech GmbH Berlin Grant Application and Coordination 650x80px

Document › Details

Thermo Fisher Scientific Inc.. (12/4/13). "Press Release: Thermo Fisher Scientific Announces Offering of Senior Notes". Waltham, MA.

	Organisation	Thermo Fisher Scientific Inc. (NYSE: TMO)
	Group	Thermo Fisher (Group)
	Product	investment banking
	Product 2	laboratory equipment and instruments
	Index term	Thermo Fisher–SEVERAL: credit, 201312 sale $900m 1.3% Senior Notes due 2017 to part-finance Life Technologies acquisition
	Index term 2	Thermo Fisher–SEVERAL: credit, 201312 sale $900m 2.4% Senior Notes due 2019 to part-finance Life Technologies acquisition
	Person	O’Brien, Ron (Thermo Fisher 201003 Director Public Relations)
	Person 2	Apicerno, Ken (Thermo Fisher 201003 Investor Relations)

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced today that it intends to offer senior notes to fund a portion of its acquisition of Life Technologies Corporation. On April 15, 2013, the company announced its agreement to acquire Life Technologies for an aggregate purchase price of approximately $13.6 billion.

The joint book-running managers for the offering are Barclays Capital Inc., J.P. Morgan Securities LLC and RBS Securities Inc.

Thermo Fisher has filed a registration statement on Form S-3 (including a prospectus) with the Securities and Exchange Commission (the "SEC") for this offering. Prospective investors should read the prospectus forming a part of that registration statement and the preliminary prospectus supplement related to the offering and the other documents that the company has filed with the SEC for more complete information about the company and this offering. These documents are available at no charge by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, these documents will be made available upon request by the company or by any underwriter or dealer participating in the offering. Interested parties may obtain a prospectus or the related preliminary prospectus supplement from Barclays Capital Inc. by directing a request to Barclays Capital Inc. c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by writing barclaysprospectus@broadridge.com or by calling 1-888-603-5847; from J.P. Morgan Securities LLC by directing a request to J.P. Morgan Securities LLC, 383 Madison Avenue, New York, NY 10179, Attn: Investment Grade Syndicate Desk - 3rd Floor, or by calling 212-834-4533; or from RBS Securities Inc. by directing a request to RBS Securities Inc., 600 Washington Boulevard, Stamford, CT 06901, Attn: Syndicate, or by calling 866-884-2071.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy the notes, nor shall there be any offer, solicitation or sale of the notes in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

Contact:

Thermo Fisher Scientific Inc.
Ron O'Brien, 781-622-1242
ron.obrien@thermofisher.com
or
Ken Apicerno, 781-622-1294
ken.apicerno@thermofisher.com
www.thermofisher.com

Record changed: 2020-03-09